Business Wire

New Data Presented at ECTRIMS Show Evobrutinib is First BTK Inhibitor to Demonstrate a Significant Reduction in Slowly Expanding Lesions (SEL) in Patients with RMS

Share

Merck, a leading science and technology company, today shared data in an oral presentation from a Phase II post-hoc analysis, demonstrating that the oral, central nervous system (CNS)-penetrant, fully covalent Bruton’s tyrosine kinase inhibitor (BTKi) evobrutinib impacted brain lesions associated with chronic inflammation in the CNS, making it the first BTKi to show significant reductions in slowly expanding lesions (SEL). SELs are chronic, active, demyelinated multiple sclerosis (MS) lesions, which are thought to be an early indicator of disease progression in MS. These data were presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) days after the completion of enrolment into the Phase III EVOLUTION RMS program, in which evobrutinib is being investigated, was announced.

“The presented analysis is the first to show a BTK inhibitor significantly reducing SEL volume in patients with relapsing MS, providing further evidence to support the mechanism of action of evobrutinib in the treatment of RMS and underscoring the molecule’s potential impact on neurodegeneration and disease progression,” said Dr. Xavier Montalban, Chairman & Director Neurology-Neuroimmunology Department & Neurorehabilitation Unit, Multiple Sclerosis Centre of Catalonia (Cemcat), Vall d'Hebron University Hospital, Barcelona, Spain.

The analysis from the Phase II study evaluated the effect of evobrutinib treatment on SEL volume from baseline to Week 48. Evobrutinib reduced SEL volume compared to placebo in a dose-dependent manner with the highest effect with 75mg twice daily (p=0.047). In a subgroup analysis, the effect of evobrutinib on SEL volume was also especially apparent in patients with more advanced disease. SELs are a potential result of accumulating neuronal damage, especially axonal loss, and occur independently of acute inflammation associated with gadolinium-enhancing (Gd+) lesions. These results, combined with the reduction in Gd+ lesions reported previously, suggest that evobrutinib reduces both acute and chronic neuroinflammation that together lead to worsening disability.

In addition to SEL volume measurement, assessing blood neurofilament light chain (NfL) levels is another emerging method to evaluate MS disease progression. Previously shared data showed that evobrutinib significantly lowers blood NfL levels as early as week 12, with levels remaining reduced at the last analyses time point at 24 weeks. New data from a second ECTRIMS oral presentation of a post-hoc analysis of the Phase II trial demonstrated that high levels of NfL at baseline were predictive of increased relapse and magnetic resonance imaging (MRI) lesion activity. Evobrutinib 75mg once daily or twice daily reduced MRI and relapse outcomes versus placebo or evobrutinib 25mg once daily over 24 weeks, even in more advanced MS subjects with high baseline NfL levels. These initial findings across NfL data combined with SEL data continue to show evobrutinib’s potential benefit in disease progression.

The most extensive integrated safety dataset of a BTKi in autoimmune diseases was also presented. The analysis, which utilized pooled data from three Phase II trials across systemic lupus erythematosus, rheumatoid arthritis and RMS from 1083 patients, included different doses of 25mg or 75mg once daily, or 50mg or 75mg twice daily. Evobrutinib was generally well tolerated with similar rates of adverse events between evobrutinib and placebo by indication and across trials. The most common adverse events reported were urinary tract infections (9.5% versus 8.5% placebo), nasopharyngitis (7.3% versus 5.5% placebo), diarrhea (6.2% versus 4.8% placebo) and alanine aminotransferase (ALT) increase (2.9% versus 1.5% placebo). Liver transaminase elevations were asymptomatic and reversible upon treatment discontinuation.

“New treatments are needed that target chronic neuroinflammation early in RMS to effectively prevent progression and accumulation of disability,” said Danny Bar-Zohar, MD, Global Head of Development for the Healthcare business of Merck. “Evobrutinib’s first of its kind BTKi data on both SEL and NfL, which are thought to predict disease progression, further substantiate our belief in evobrutinib’s potential as a best-in-class treatment for people living with relapsing MS.”

About Evobrutinib

Evobrutinib (M2951) is in clinical development to investigate its potential as a treatment for multiple sclerosis (MS). It is an oral, highly selective inhibitor of Bruton’s tyrosine kinase (BTK) which is important in the development and functioning of various immune cells including B lymphocytes and macrophages. Evobrutinib is designed to inhibit primary B cell responses such as proliferation and antibody and cytokine release, without directly affecting T cells. Evobrutinib is currently under clinical investigation and not approved for any use anywhere in the world.

About Multiple Sclerosis

Multiple sclerosis (MS) is a chronic, inflammatory condition of the central nervous system and is the most common non-traumatic, disabling neurological disease in young adults. It is estimated that approximately 2.8 million people have MS worldwide. While symptoms can vary, the most common symptoms of MS include blurred vision, numbness or tingling in the limbs and problems with strength and coordination. The relapsing forms of MS are the most common.

Merck in Neurology and Immunology

Merck has a long-standing legacy in neurology and immunology, with significant R&D and commercial experience in multiple sclerosis (MS). The company`s current MS portfolio includes two products for the treatment of relapsing MS – Rebif® (interferon beta-1a) and MAVENCLAD® (cladribine tablets). Merck aims to improve the lives of patients by addressing areas of unmet medical needs. In addition to Merck`s commitment to MS, the company also has a pipeline focusing on discovering new therapies that have the potential in other neuroinflammatory and immune-mediated diseases, including systemic lupus erythematosus (SLE).

All Merck Press Releases are distributed by e-mail at the same time they become available on the Merck Website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.

About Merck

Merck, a leading science and technology company, operates across healthcare, life science and electronics. Around 58,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2020, Merck generated sales of € 17.5 billion in 66 countries.

Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Electronics.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Tone Brauti Fritzen
tone-brauti.fritzen@merckgroup.com
Phone: +49 151 1454 2694

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Quantfury Introduces Fractional Trading Mode for Stocks, ETFs and Commodities28.11.2022 19:00:00 CET | Press release

Quantfury Trading Limited (“Quantfury”), a global brokerage firm that delivers commission-free trading and investing at real-time spot prices of global and crypto exchanges, today announced the launch of fractional trading mode with more than 1500+ stocks, ETFs and commodity futures contracts available to trade on the Quantfury platform. Quantfurians can now buy and sell fractional shares of all stocks, ETFs and commodity futures contracts at their real-time US and European exchanges spot prices with zero commissions and borrowing fees, providing improved trading and investment experience. “Quantfury is advancing its unmatched trading and investing conditions further by making it even more affordable to Quantfurians out there,” said Daniel Muvdi, Quantfury’s Head of Markets. “Fractional trading mode opens up more trading opportunities to the Quantfury global audience of more than 400,000 Quantfurians.” Fractional trading mode is available on all Quantfury trading platforms immediately,

The 4 th World Science and Technology Development Forum Held in Chengdu28.11.2022 17:06:00 CET | Press release

The 4th World Science and Technology Development Forum with the theme “Openness, Trust and Cooperation” kicked off in Chengdu on November 27, 2022, which was attended by more than 300 top experts and scholars, representatives of international organizations, and entrepreneurs, from more than 20 countries and regions, including 7 Nobel laureates and more than 60 academicians home and abroad. Together, they discussed technological innovation and sustainable development in key fields such as basic science, climate change, digital economy, and green innovation, and proposed technological innovation solutions to address the challenges of today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221128005539/en/ The 4th World Science and Technology Development Forum Held in Chengdu (Photo: Business Wire) The world today is facing many challenges, such as the COVID-19 pandemic, energy security, food security, climate change, poverty, an

Biocytogen Enters into Antibody Agreement with ADC Therapeutics28.11.2022 15:47:00 CET | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) today announced that it has entered into an evaluation and option agreement with ADC Therapeutics SA. Biocytogen will grant ADC Therapeutics a license to evaluate Biocytogen’s proprietary antibodies against three tumor targets, with an option to license selected antibodies at a later date for global ADC development and commercialization. Biocytogen reserves all global rights for these antibodies beyond ADC development. Biocytogen will receive an upfront payment. For each option exercised, Biocytogen will be entitled to an option-exercise fee, and development and commercial milestone payments, which potentially total tens of millions of US dollars, as well as single-digit royalties on net sales. Under the agreement, Biocytogen will provide ADC Therapeutics with monoclonal and/or biparatopic antibodies directed against three tumor targets, generated through Biocytogen’s Project Integrum (also called RenMiceTM HiTS

Medimaps Group Appoints Meinhard F. Schmidt as Board Chairman; Adds Anne Le Grand and Five Additional Board Members28.11.2022 15:15:00 CET | Press release

Medimaps Group (www.medimapsgroup.com), a Swiss/Global med-tech company specializing in image processing software for assessing bone health, today announced new appointments to its Board of Directors, effective immediately. Meinhard F. Schmidt, an international MedTech/BioTech and Digital Health executive with 25+ years of experience, has been named Board Chairman; and Anne Le Grand,an accomplished healthcare executive and consultant with 30+ years in the global healthcare technology industry, has joined as an independent board member. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221128005146/en/ Medimaps Group Announces Board Members: Meinhard F. Schmidt as Board Chairman, and Anne Le Grand Plus Five Other Members and One Strategic Advisor. (Photo: Business Wire) Five additional board members and one board advisor have also been named, bolstering Medimaps investment and clinical policy expertise. Visit Medimaps website fo

Viz.ai Appoints Radiology Advisory Board to Advance Innovation28.11.2022 14:00:00 CET | Press release

Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced the creation of its Radiology Advisory Board to assist Viz.ai in the development of strategy and products to support radiologists and patients. The Board consists of 14 leading healthcare experts with diverse experience and roles in radiology. “I am honored to co-chair the Radiology Advisory Board and excited about Viz.ai’s commitment to customers and patients to invest in innovation that increases access to life-saving therapies,” said Kevin Abrams, MD, medical director of neuroradiology and MRI and chief of radiology at Baptist Hospital in Miami. “I am looking forward to the rich dialogue to be discussed in our inaugural meeting, exploring future ideas.” “I’m looking forward to working with these esteemed board members to help shape Viz.ai’s Radiology Program through patient-centric vision, passion, and insights,” said Suzie Bash, MD, Co-Chair of the Viz.ai Radiology Advisory Board a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom